REM3
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
15/09/2025
Voltar para busca
Dado oficial do USPTO
VIJOICE
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: MistaEscritório: US
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
33
Atualização mais recente
16/09/2025
Classificação
Registrada
Tipo de marca
Mista
Classes Nice
5
Data de depósito
28/01/2020
Data de registro
15/09/2020
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
15/09/2020
Última transação
16/09/2025
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Código do desenho
3
Tipo de titular
99
Localização do titular
CH
Examinador
STADELI, MARTA
Unidade examinadora
N50
Localização atual
PUBLICATION AND ISSUE SECTION
Descrição da marca
The mark consists of the wording "VIJOICE" in lilac stylized font with seven circles in shades of green over the letters "ijoic" with circles making the dots over the letters "i" and "j" and with the circles changing in size and color from left to right from large to small and from green to light green.
Titulares e representantes
Titulares
NOVARTIS AG
Representantes
Maury M. Tepper, III Tepper & Eyster, PLLC
Classificação técnica
Classes Nice
Classe 5
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 5
Anti-infectives; anti-inflammatories; antibacterial pharmaceuticals; antibiotics; antifungal preparations; antivirals; cardiovascular pharmaceuticals; dermatological pharmaceutical preparations; inhaled pharmaceutical preparations for the prevention and treatment of respiratory diseases and disorders; pharmaceutical preparations acting on the central nervous system; pharmaceutical preparations and substances for the prevention and treatment of gastrointestinal diseases; pharmaceutical preparations for the prevention and treatment of diseases and disorders of the autoimmune systemthe metabolic systemthe endocrine systemthe musculo-skeletal system and the genitourinary system; pharmaceutical preparations for use in hematology and in tissue and organ transplantation; pharmaceutical preparations for the prevention and treatment of eye diseases and conditions; pharmaceutical preparations for the prevention and treatment of heart rhythm disorders; pharmaceutical preparations for the prevention and treatment of immune system related diseases and disorders; pharmaceutical preparations for the prevention and treatment of kidney diseases; pharmaceutical preparations for the prevention and treatment of diabetes; pharmaceutical preparations for the prevention and treatment of hypertension; pharmaceutical preparations for the prevention and treatment of skin disorders; pharmaceutical preparations for use in dermatology; pharmaceutical preparations for use in urology; pharmaceutical preparations for use in ophthalmology; pharmaceutical preparations for the prevention and treatment of cancer and tumors; pharmaceutical preparations for the prevention and treatment of allergies; pharmaceutical preparations for the prevention and treatment of bone diseases; pharmaceutical preparations for the prevention and treatment of respiratory diseases and asthma
Publicações
Histórico de despachos e eventos da marca no USPTO.
33 publicações encontradas
FINV
FINAL DECISION TRANSACTION PROCESSED BY IB
30/01/2021
XXSS
GENERIC MADRID TRANSACTION SENT TO IB
02/01/2021
XXCR
GENERIC MADRID TRANSACTION CREATED
02/01/2021
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
15/12/2020
R.PR
REGISTERED-PRINCIPAL REGISTER
15/09/2020
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
30/06/2020
PUBO
PUBLISHED FOR OPPOSITION
30/06/2020
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
10/06/2020
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
27/05/2020
XAEC
EXAMINER'S AMENDMENT ENTERED
27/05/2020
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
27/05/2020
GNEA
EXAMINERS AMENDMENT E-MAILED
27/05/2020
CNEA
EXAMINERS AMENDMENT -WRITTEN
27/05/2020
RFNT
REFUSAL PROCESSED BY IB
23/05/2020
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
18/05/2020
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
17/05/2020
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
17/05/2020
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
15/05/2020
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
15/05/2020
ECDR
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
15/05/2020
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
15/05/2020
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
15/05/2020
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
15/05/2020
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
04/05/2020
RFRR
REFUSAL PROCESSED BY MPU
04/05/2020
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
18/04/2020
CNRT
NON-FINAL ACTION WRITTEN
17/04/2020
DOCK
ASSIGNED TO EXAMINER
15/04/2020
MAFR
APPLICATION FILING RECEIPT MAILED
07/04/2020
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
03/04/2020
LIMI
LIMITATION FROM ORIGINAL APPLICATION ENTERED
31/03/2020
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
26/03/2020
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace VIJOICE ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.